Catalogue

Background
Protects against mitochondrial dysfunction during cellular stress, potentially by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy). It is necessary for PARK2 recruitment to dysfunctional mitochondria to initiate their degradation. Defects in PINK1 are the cause of Parkinson disease type 6 (PARK6). A neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep.

Synonyms: PTEN-induced putative kinase protein 1

Source

Immunogen: Synthetic peptide derived from the human PINK1 protein. Control for antibody to G309D mutant (Cat. No. X2761P)

Product

Product Form: Affinity Purified

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Antigen Immunoaffiinity Purification

Concentration: See vial for concentration

Applications
Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Western Blotting

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Matsuda, N., et al. ‘PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy.’ J. Cell. Biol., 189, 211-221 (2010) 2. Vives-Bauza, C., et al. ‘PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.’ Proc. Natl. Acad. Sci. USA, 107, 378-383 (2010) 3. Valente, E.M., et al. ‘PINK1 mutations are associated with sporadic early-onset parkinsonism.’ Ann. Neurol., 56, 336-341 (2004) 4. Geisler, S., et al. ‘The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations.’ Autophagy, 6, 871-878 (2010) 5. Valente, E.M., et al. ‘Hereditary early-onset Parkinson's disease caused by mutations in PINK1.’ Science, 304, 1158-1160 (2004) 6. Silvestri, L., et al. ‘Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism.’ Hum. Mol. Genet., 14, 3477-3492 (2005)

Protein Reference(s)

Database Name: SwissProt

Accession Number: Q9BXM7

Species Accession: Human

Safety Datasheet(s) for this product: